An analysis of COVID-19 related interventional clinical trials registered globally

Findings and call to action

Globally, over 2,180 COVID-19-related interventional clinical trials are underway across 93 countries. Only 4% of trials are collecting evidence in more than one country and less than 15% focus on prevention aspects of the pandemic.

We need a global research agenda to prioritise, coordinate and generate evidence that not only helps us manage the current pandemic, but enables us to build back better.

Of all COVID-19-related interventional clinical trials registered globally, just 5% were found to focus on NCD control in the context of the pandemic and less than 4% focus specifically on people with at least one NCD.

We need more clinical trials focused on the intersection between NCDs and COVID-19 to understand how we can mitigate both direct and indirect impacts of the pandemic.

Of all COVID-19-related interventional clinical trials exclusively including people living with one or more NCDs, more than 73% focus on pharmacological interventions.

We need to build the evidence base on a broader range of interventions designed to address COVID-19 in those with NCDs, including educational and behavioural interventions.

Researchers from The George Institute downloaded data on COVID-19-related clinical trials from the World Health Organization International Clinical Trials Registry Platform on 29 June 2020, to identify registered interventional clinical trials and map how these relate to Non-Communicable Diseases (NCDs).

You can read the results in full at www.georgeinstitute.org/building-back-better-after-covid-19-the-research-agenda

#BuildingBackBetter
#COVID19
#ActOnNCDs